 |
 |
|||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
T2 Prostate Cancer Trial (Complete) - Canada In Spring, 2002, Oncolytics initiated a clinical trial examining the use of REOLYSIN® in cancer confined to the prostate gland. The primary endpoints of this study were to examine safety and the histopathology of prostate tissue post-therapy and post-prostactectomy. Patients were treated with a single injection of REOLSYIN® directly into the prostate gland. Final results showed evidence of apoptotic tumour cell death in four of six patients, with no safety concerns. A fifth patient saw PSA level drop by 53% and the prostate gland shrank by 67% from just prior to injection to surgical removal of the prostate gland three weeks later. See related press releases: February 27, 2004 - Oncolytics Biotech Provides Final Update on T2 Prostate Cancer Study March 31, 2003 - Oncolytics Biotech Inc. Reports Presentation of Results From Interim Assessment of T2 Prostate Cancer Trial April 16, 2002 - Oncolytics Biotech Inc. Starts First Patient Treatment In Prostate Cancer Trial October 11, 2001 - Oncolytics Biotech Inc. Announces Approval to Proceed with Clinical Trial to Evaluate REOLYSIN® for the Treatment of Prostate Cancer
|
|
|||||||||||
 |
|
 |